These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 19468028)

  • 1. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
    Koh WJ; Kwon OJ; Gwak H; Chung JW; Cho SN; Kim WS; Shim TS
    J Antimicrob Chemother; 2009 Aug; 64(2):388-91. PubMed ID: 19468028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients.
    Koh WJ; Kang YR; Jeon K; Kwon OJ; Lyu J; Kim WS; Shim TS
    J Antimicrob Chemother; 2012 Jun; 67(6):1503-7. PubMed ID: 22403262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
    Park IN; Hong SB; Oh YM; Kim MN; Lim CM; Lee SD; Koh Y; Kim WS; Kim DS; Kim WD; Shim TS
    J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.
    Anger HA; Dworkin F; Sharma S; Munsiff SS; Nilsen DM; Ahuja SD
    J Antimicrob Chemother; 2010 Apr; 65(4):775-83. PubMed ID: 20150181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linezolid in the treatment of multidrug-resistant tuberculosis.
    Schecter GF; Scott C; True L; Raftery A; Flood J; Mase S
    Clin Infect Dis; 2010 Jan; 50(1):49-55. PubMed ID: 19947856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid in the treatment of MDR-TB: a retrospective clinical study.
    Xu HB; Jiang RH; Li L; Xiao HP
    Int J Tuberc Lung Dis; 2012; 16(3):358-63. PubMed ID: 22640450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases.
    von der Lippe B; Sandven P; Brubakk O
    J Infect; 2006 Feb; 52(2):92-6. PubMed ID: 15907341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
    Yew WW; Chang KC; Chau CH
    J Antimicrob Chemother; 2009 Nov; 64(5):1119; author reply 1119-20. PubMed ID: 19666903
    [No Abstract]   [Full Text] [Related]  

  • 9. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response.
    Koh WJ; Shim TS
    J Antimicrob Chemother; 2009 Nov; 64(5):1119-20. PubMed ID: 19744986
    [No Abstract]   [Full Text] [Related]  

  • 10. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.
    Migliori GB; Eker B; Richardson MD; Sotgiu G; Zellweger JP; Skrahina A; Ortmann J; Girardi E; Hoffmann H; Besozzi G; Bevilacqua N; Kirsten D; Centis R; Lange C;
    Eur Respir J; 2009 Aug; 34(2):387-93. PubMed ID: 19282348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand.
    Roongruangpitayakul C; Chuchottaworn C
    J Med Assoc Thai; 2013 Oct; 96(10):1273-82. PubMed ID: 24350407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India.
    Singla R; Caminero JA; Jaiswal A; Singla N; Gupta S; Bali RK; Behera D
    Eur Respir J; 2012 Apr; 39(4):956-62. PubMed ID: 21965225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.
    Nam HS; Koh WJ; Kwon OJ; Cho SN; Shim TS
    Int J Antimicrob Agents; 2009 Jan; 33(1):92-3. PubMed ID: 18789655
    [No Abstract]   [Full Text] [Related]  

  • 15. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid for the treatment of multidrug-resistant tuberculosis.
    Fortún J; Martín-Dávila P; Navas E; Pérez-Elías MJ; Cobo J; Tato M; De la Pedrosa EG; Gómez-Mampaso E; Moreno S
    J Antimicrob Chemother; 2005 Jul; 56(1):180-5. PubMed ID: 15911549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
    Alffenaar JW; van Altena R; Harmelink IM; Filguera P; Molenaar E; Wessels AM; van Soolingen D; Kosterink JG; Uges DR; van der Werf TS
    Clin Pharmacokinet; 2010 Aug; 49(8):559-65. PubMed ID: 20608757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis.
    Schaaf HS; Willemse M; Donald PR
    Pediatr Infect Dis J; 2009 Aug; 28(8):748-50. PubMed ID: 19633523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
    Sotgiu G; Lange C; Richardson MD; Matteelli A; Centis R; Eker B; Guenther G; Spanevello A; Migliori GB;
    J Antimicrob Chemother; 2009 Oct; 64(4):879-83; author reply 883-4. PubMed ID: 19651787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.